Terms: = Lung cancer AND PIM1, PIM, 5292, ENSG00000137193, P11309 AND Treatment
19 results:
1. Trends in Survival Rates of Non-Small Cell lung cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020.
Chi SA; Yu H; Choi YL; Park S; Sun JM; Lee SH; Ahn JS; Ahn MJ; Choi DH; Kim K; Jung HA; Park K
JAMA Netw Open; 2023 Mar; 6(3):e232002. PubMed ID: 36929402
[TBL] [Abstract] [Full Text] [Related]
2. Association of polypharmacy and potential drug-drug interactions with adverse treatment outcomes in older adults with advanced cancer.
Mohamed MR; Mohile SG; Juba KM; Awad H; Wells M; Loh KP; Flannery M; Culakova E; Tylock RG; Ramsdale EE
Cancer; 2023 Apr; 129(7):1096-1104. PubMed ID: 36692475
[TBL] [Abstract] [Full Text] [Related]
3. Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients.
Ntzifa A; Strati A; Kallergi G; Kotsakis A; Georgoulias V; Lianidou E
Sci Rep; 2021 Jan; 11(1):2313. PubMed ID: 33504904
[TBL] [Abstract] [Full Text] [Related]
4. Polypharmacy among older advanced lung cancer patients taking EGFR tyrosine kinase inhibitors.
Hakozaki T; Matsuo T; Shimizu A; Ishihara Y; Hosomi Y
J Geriatr Oncol; 2021 Jan; 12(1):64-71. PubMed ID: 32952094
[TBL] [Abstract] [Full Text] [Related]
5. Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity
Ohol YM; Sun MT; Cutler G; Leger PR; Hu DX; Biannic B; Rana P; Cho C; Jacobson S; Wong ST; Sanchez J; Shah N; Pookot D; Abraham B; Young K; Suthram S; Marshall LA; Bradford D; Kozon N; Han X; Okano A; Maung J; Colas C; Schwarz J; Wustrow D; Brockstedt DG; Kassner PD
Mol Cancer Ther; 2020 Oct; 19(10):1970-1980. PubMed ID: 32788207
[TBL] [Abstract] [Full Text] [Related]
6. Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with cancer Receiving First-Line Palliative Chemotherapy.
Hong S; Lee JH; Chun EK; Kim KI; Kim JW; Kim SH; Lee YG; Hwang IG; Kim JY; Koh SJ; Ko YH; Shin SH; Woo IS; Kim TY; Baek JY; Kim HJ; Kim HJ; Lee MA; Kwon JH; Hong YS; Ryoo HM; Kim JH
Oncologist; 2020 Mar; 25(3):e502-e511. PubMed ID: 32162799
[TBL] [Abstract] [Full Text] [Related]
7. pim kinases alter mitochondrial dynamics and chemosensitivity in lung cancer.
Chauhan SS; Toth RK; Jensen CC; Casillas AL; Kashatus DF; Warfel NA
Oncogene; 2020 Mar; 39(12):2597-2611. PubMed ID: 31992853
[TBL] [Abstract] [Full Text] [Related]
8. Effect of pim-3 Downregulation on Proliferation and Apoptosis in lung Adenocarcinoma A549 Cells.
Fan X; Xie Y; Zhang L; Gao X; Han J; Chen Y; Yang J; Li S
Ann Clin Lab Sci; 2019 Nov; 49(6):770-776. PubMed ID: 31882428
[TBL] [Abstract] [Full Text] [Related]
9. The targetable kinase pim1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.
Trigg RM; Lee LC; Prokoph N; Jahangiri L; Reynolds CP; Amos Burke GA; Probst NA; Han M; Matthews JD; Lim HK; Manners E; Martinez S; Pastor J; Blanco-Aparicio C; Merkel O; de Los Fayos Alonso IG; Kodajova P; Tangermann S; Högler S; Luo J; Kenner L; Turner SD
Nat Commun; 2019 Nov; 10(1):5428. PubMed ID: 31780656
[TBL] [Abstract] [Full Text] [Related]
10. Hispidulin suppresses cell growth and metastasis by targeting pim1 through JAK2/STAT3 signaling in colorectal cancer.
Liu K; Gao H; Wang Q; Wang L; Zhang B; Han Z; Chen X; Han M; Gao M
Cancer Sci; 2018 May; 109(5):1369-1381. PubMed ID: 29575334
[TBL] [Abstract] [Full Text] [Related]
11. Potential Medication-Related Problems in Older Breast, Colon, and lung cancer Patients in the United States.
Lund JL; Sanoff HK; Peacock Hinton S; Muss HB; Pate V; Stürmer T
Cancer Epidemiol Biomarkers Prev; 2018 Jan; 27(1):41-49. PubMed ID: 28978563
[No Abstract] [Full Text] [Related]
12. pim1 knockdown inhibits cell proliferation and invasion of mesothelioma cells.
Mawas AS; Amatya VJ; Suzuki R; Kushitani K; Mohi El-Din MM; Takeshima Y
Int J Oncol; 2017 Mar; 50(3):1029-1034. PubMed ID: 28197633
[TBL] [Abstract] [Full Text] [Related]
13. Activation of pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors.
An N; Xiong Y; LaRue AC; Kraft AS; Cen B
Cancer Res; 2015 Dec; 75(24):5318-28. PubMed ID: 26670562
[TBL] [Abstract] [Full Text] [Related]
14. XCR1 promotes cell growth and migration and is correlated with bone metastasis in non-small cell lung cancer.
Wang T; Han S; Wu Z; Han Z; Yan W; Liu T; Wei H; Song D; Zhou W; Yang X; Xiao J
Biochem Biophys Res Commun; 2015 Aug; 464(2):635-41. PubMed ID: 26166822
[TBL] [Abstract] [Full Text] [Related]
15. Kaempferol enhances the suppressive function of Treg cells by inhibiting FOXP3 phosphorylation.
Lin F; Luo X; Tsun A; Li Z; Li D; Li B
Int Immunopharmacol; 2015 Oct; 28(2):859-65. PubMed ID: 25870037
[TBL] [Abstract] [Full Text] [Related]
16. pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer.
Pang W; Tian X; Bai F; Han R; Wang J; Shen H; Zhang X; Liu Y; Yan X; Jiang F; Xing L
Mol Cancer; 2014 Oct; 13():240. PubMed ID: 25342548
[TBL] [Abstract] [Full Text] [Related]
17. pim1 kinase inhibitors induce radiosensitization in non-small cell lung cancer cells.
Kim W; Youn H; Kwon T; Kang J; Kim E; Son B; Yang HJ; Jung Y; Youn B
Pharmacol Res; 2013 Apr; 70(1):90-101. PubMed ID: 23352980
[TBL] [Abstract] [Full Text] [Related]
18. pim1-activated PRAS40 regulates radioresistance in non-small cell lung cancer cells through interplay with FOXO3a, 14-3-3 and protein phosphatases.
Kim W; Youn H; Seong KM; Yang HJ; Yun YJ; Kwon T; Kim YH; Lee JY; Jin YW; Youn B
Radiat Res; 2011 Nov; 176(5):539-52. PubMed ID: 21910584
[TBL] [Abstract] [Full Text] [Related]
19. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1.
Nasser MW; Datta J; Nuovo G; Kutay H; Motiwala T; Majumder S; Wang B; Suster S; Jacob ST; Ghoshal K
J Biol Chem; 2008 Nov; 283(48):33394-405. PubMed ID: 18818206
[TBL] [Abstract] [Full Text] [Related]
